STOCKHOLM, February 21, 2022 — When CombiGene signed an agreement with a potential value of USD 328.5 million with Spark Therapeutics in the autumn of 2021, a major leap was taken in the company’s development and established CombiGene as an internationally recognized gene therapy company.
The agreement is of course extremely important and means that the epilepsy project CG01 has now been given the very best conditions to reach all the way to global commercialization and thus reach epilepsy patients who currently lack treatment options.
The agreement also means that CombiGene has shown that the company’s business model can establish partnerships among the largest players in the international pharmaceutical industry. Spark is part of the Roche Group, the world’s third-largest pharmaceutical company.
To better reflect CombiGene’s strengthened position, the company has recently launched a new website. The address is the same as before – combigene.com
Please visit it!
